NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
Incyte Corporation
Gilead Sciences
Acepodia Biotech, Inc.
Juventas Cell Therapy Ltd.
Sabz Biomedicals
Hebei Senlang Biotechnology Inc., Ltd.